Original paper

Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease

Volume: 15, Issue: 4, Pages: 465 - 473
Published: Mar 4, 2020
Abstract
The glucagon-like peptide-1 receptor agonist liraglutide demonstrated cardiovascular and kidney benefits in the LEADER trial, particularly in participants with CKD.This post hoc analysis evaluated the safety of liraglutide treatment in patients with CKD in LEADER. Overall, 9340 patients were randomized to liraglutide or placebo, both in addition to standard of care. Of those, 2158 patients had CKD versus 7182 without CKD (defined as eGFR <60...
Paper Details
Title
Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease
Published Date
Mar 4, 2020
Volume
15
Issue
4
Pages
465 - 473
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.